In particular, HER3 up-regulation has been correlated with resistance to HER2-targeting inhibitors in breast cancer due to the unique ability of the HER2:HER3 heterodimer to activate the PI3K/AKT-mTOR signaling pathway (reviewed in [8–10]). Here, ERBB3 is linked to breast cancer.